Payment overview · 2025
General Payments
$308.70
16 reported records · 4 companies
Healthcare provider profile · identity verified
Jacquelyn Renee Mcfadden, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLORISSANT, MO · NPI 1891809646
Verified facts
What the public records show
CMS Open Payments records show Jacquelyn Renee Mcfadden, MD received $308.70 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 48.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $148.14 | 48.0% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.45 | 32.9% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.92 | 12.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.19 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $308.70 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $128.11 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $101.45 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $101.45 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $73.15 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.92 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
70 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
129 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 621 | 174 |
| Atorvastatin Calcium | Atorvastatin Calcium | 547 | 171 |
| Losartan Potassium | Losartan Potassium | 476 | 125 |
| Lisinopril | Lisinopril | 255 | 76 |
| Gabapentin | Gabapentin | 230 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 68 |
| Metformin Hcl | Metformin Hcl | 195 | 57 |
| Potassium Chloride | Potassium Chloride | 188 | 53 |
| Omeprazole | Omeprazole | 141 | 46 |
| Furosemide | Furosemide | 140 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 130 | 38 |
| Trulicity | Dulaglutide | 129 | 21 |
| Ibuprofen | Ibuprofen | 123 | 46 |
| Carvedilol | Carvedilol | 122 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 43 |
| Meloxicam | Meloxicam | 107 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 26 |
| Tramadol Hcl | Tramadol Hcl | 100 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 22 |
| Nifedipine Er | Nifedipine | 88 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 31 |
| Ozempic | Semaglutide | 77 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 24 |
| Simvastatin | Simvastatin | 77 | 26 |
| Naproxen | Naproxen | 75 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 30 |
| Allopurinol | Allopurinol | 71 | 25 |
| Jardiance | Empagliflozin | 70 | 17 |
| Montelukast Sodium | Montelukast Sodium | 70 | 24 |
| Famotidine | Famotidine | 68 | 18 |
| Glipizide Er | Glipizide | 66 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 66 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 62 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 59 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 16 |
| Metformin Hcl Er | Metformin Hcl | 54 | 14 |
| Trazodone Hcl | Trazodone Hcl | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 51 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 16 |
| Prednisone | Prednisone | 50 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 13 |
| Levemir Flexpen | Insulin Detemir | 48 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 21 |
| Ezetimibe | Ezetimibe | 44 | 13 |
| Eliquis | Apixaban | 43 | suppressed |
| Alprazolam | Alprazolam | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | 12 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Glipizide | Glipizide | 24 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 12 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 20 |
| Colchicine | Colchicine | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 18 |
| Belsomra | Suvorexant | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 14 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $308.70 · 16 records | Lilly USA, LLC | Cologuard Collection Kit, MOUNJARO, Ozempic, REXULTI, Rybelsus, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error